Syncromune

Syncromune is a clinical-stage biopharmaceutical company dedicated to saving and improving the lives of patients with advanced cancer by fully realizing the potential of intratumoral immunotherapy. The company focuses on developing next-generation personalized treatments for metastatic cancer. Its primary goal is to optimize intratumoral immunotherapy and strive to become a global leader in this new form of immunotherapy. Syncromune is advancing the development of the Syncrovax™ platform, which is applicable to several types of metastatic cancers. Syncrovax™ is an innovative platform technology that uses a combination approach to synchronize the timing and location of tumor antigen release with the functional activation of immune cells. The Syncrovax™ platform enables a patient’s immune system to create a personalized therapeutic autologous vaccine that can identify and attack cancer throughout the body. The potential impact of using Syncrovax™ to treat metastatic solid tumors is compelling and far-reaching, with the ability to meaningfully improve patient outcomes.